Letermovir
Letermovir is an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in eligible high-risk patients, particularly CMV-seropositive adults undergoing allogeneic haematopoietic stem cell transplantation and selected kidney transplant recipients. It works by inhibiting the CMV terminase complex, which is essential for processing and packaging viral DNA into new infectious virus particles. It is available as oral tablets, oral granules, and an intravenous formulation, with the route and duration of treatment determined by the transplant type and clinical protocol. Common side effects include nausea, diarrhoea, vomiting, and swelling of the limbs. Important precautions include monitoring liver function and reviewing drug interactions, particularly with immunosuppressants such as ciclosporin and tacrolimus, as letermovir can alter their blood concentrations. It should be prescribed under specialist supervision, with appropriate CMV monitoring and transplant-care follow-up.
Letermovir was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Letermovir, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Letermovir from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Letermovir, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
